Publicaciones científicas
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
Maria Victoria Mateos 1 , Katja Weisel 2 , Evangelos Terpos 3 , Sossana Delimpasi 4 , Efstathios Kastritis 3 , Elena Zamagni 5 , Michel Delforge 6 , Enrique Ocio 7 , Eirini Katodritou 8 , Francesca Gay 9 , Alessandra Larocca 9 , Xavier Leleu 10 , Paula Rodriguez Otero 11 , Fredik Schjesvold 12 , Michele Cavo 13 , Meletios A Dimopoulos 3
We, as leaders in the European myeloma clinical research community and from nine countries across the European Union, are writing in response to the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommendation to not renew the conditional marketing authorization of belantamab mafodotin issued on September 15, 2023.
Multiple myeloma (MM) is the second most frequent hematological cancer with four to five new cases per 100,000 inhabitants/year and although remarkable progress has occurred in the last years, it does remain for most patients an incurable disease.1
There are three main drug classes used for the treatment of MM: proteasome inhibitors, immunomodulatory drugs and CD38 monoclonal antibodies, all of which are now part of the standard of care for patients with MM in early lines of therapy. However, when patients become triple class exposed and/or refractory to these treatments, they typically have poor outcomes,2 thus representing an unmet medical need with a lack of new standards of care options in this population.
CITA DEL ARTÍCULO Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284694